Gastrointestinal Cancer

Patient Characteristics Linked to Time on Treatment and Survival in Patients With mCRC Receiving Cetuximab

June 11, 2021

KRAS mutational status and geographical region were associated with time on treatment (TOT), and body mass index (BMI) and age were linked with overall survival (OS) in patients with metastatic colorectal cancer mCRC) being treated with second-line cetuximab (Erbitux) after irinotecan or oxaliplatin-based regimens.

FDA Approves Frontline Pembrolizumab for HER2+ Gastric, GEJ Cancer

May 05, 2021

The FDA granted an accelerated approval to pembrolizumab plus trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Immunotherapy Regimen Continues to Improve GI Treatment

April 29, 2021

With immunotherapy options expanding for patients with a range of gastrointestinal cancers to include combination strategies with chemotherapy, their use in the treatment course should come sooner rather than later for those with high PD-L1 expression.